BG Medicine Effects One-for-Four Reverse Stock Split | GenomeWeb

NEW YORK (GenomeWeb) – BG Medicine said on Wednesday that it has effected a one-for-four reverse stock split to remain listed on the Nasdaq.

The reverse split increases the share price of the company's stock above the minimum $1 bid price to continue listing on the Nasdaq Capital Market. The firm's shares opened at $1.61 per share today after closing at $.43 per share on Wednesday. In early morning trading, the stock rose to $2 per share.

The stock split reduced the number of BG Medicine's common shares outstanding to about 8.6 million shares from about 34.6 million shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.